Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.

Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.

Melkersson KI, Hulting AL, Brismar KE.

J Clin Psychiatry. 2000 Oct;61(10):742-9.

PMID:
11078035
3.
5.
6.

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

Kinon BJ, Basson BR, Gilmore JA, Tollefson GD.

J Clin Psychiatry. 2001 Feb;62(2):92-100.

PMID:
11247108
7.

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

Atmaca M, Kuloglu M, Tezcan E, Ustundag B.

J Clin Psychiatry. 2003 May;64(5):598-604.

PMID:
12755665
8.

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.

Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.

Am J Psychiatry. 2003 Feb;160(2):290-6.

PMID:
12562575
9.

The effects of novel antipsychotics on glucose and lipid levels.

Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC.

J Clin Psychiatry. 2002 Oct;63(10):856-65.

PMID:
12416594
10.

Olanzapine increases weight and serum triglyceride levels.

Osser DN, Najarian DM, Dufresne RL.

J Clin Psychiatry. 1999 Nov;60(11):767-70.

PMID:
10584766
11.

Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol.

Atmaca M, Kuloglu M, Tezcan E, Gecici O, Ustundag B.

Schizophr Res. 2003 Mar 1;60(1):99-100. No abstract available.

PMID:
12505146
12.

Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.

Baptista T, Rangel N, Fernández V, Carrizo E, El Fakih Y, Uzcátegui E, Galeazzi T, Gutiérrez MA, Servigna M, Dávila A, Uzcátegui M, Serrano A, Connell L, Beaulieu S, de Baptista EA.

Schizophr Res. 2007 Jul;93(1-3):99-108. Epub 2007 May 8.

PMID:
17490862
13.

Olanzapine induces insulin resistance: results from a prospective study.

Ebenbichler CF, Laimer M, Eder U, Mangweth B, Weiss E, Hofer A, Hummer M, Kemmler G, Lechleitner M, Patsch JR, Fleischhacker WW.

J Clin Psychiatry. 2003 Dec;64(12):1436-9.

PMID:
14728104
14.

Nizatidine treatment and its relationship with leptin levels in patients with olanzapine-induced weight gain.

Atmaca M, Kuloglu M, Tezcan E, Ustundag B.

Hum Psychopharmacol. 2003 Aug;18(6):457-61.

PMID:
12923824
15.

Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.

Narula PK, Rehan HS, Unni KE, Gupta N.

Schizophr Res. 2010 May;118(1-3):218-23. doi: 10.1016/j.schres.2010.02.001. Epub 2010 Mar 7.

PMID:
20207521
16.

Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis.

Henderson DC, Copeland PM, Borba CP, Daley TB, Nguyen DD, Cagliero E, Evins AE, Zhang H, Hayden DL, Freudenreich O, Cather C, Schoenfeld DA, Goff DC.

J Clin Psychiatry. 2006 May;67(5):789-97.

PMID:
16841629
17.

Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia.

Hosojima H, Togo T, Odawara T, Hasegawa K, Miura S, Kato Y, Kanai A, Kase A, Uchikado H, Hirayasu Y.

J Psychopharmacol. 2006 Jan;20(1):75-9. Epub 2005 Oct 4.

PMID:
16204328
19.

Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis.

Graham KA, Perkins DO, Edwards LJ, Barrier RC Jr, Lieberman JA, Harp JB.

Am J Psychiatry. 2005 Jan;162(1):118-23.

PMID:
15625209
20.

Supplemental Content

Support Center